22157.jpg
Global Hospital Acquired Disease Testing Market (2021 to 2026) - Industry Trends, Share, Size, Growth, Opportunity and Forecasts
May 27, 2021 06:58 ET | Research and Markets
Dublin, May 27, 2021 (GLOBE NEWSWIRE) -- The "Hospital Acquired Disease Testing Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2021-2026" report has been added to...
22157.jpg
Global Diagnostic Biomarkers Markets, 2015-2024 with 2020 as the Base Year
May 07, 2021 05:48 ET | Research and Markets
Dublin, May 07, 2021 (GLOBE NEWSWIRE) -- The "The World Market for Diagnostic Biomarkers (Tumor, Cardiac, Infectious Disease, Auto-Immune and Others)" report has been added to...
22157.jpg
Global Molecular Diagnostics for Infectious Disease Market Report 2021-2025: Microbiology Lab May Disappear While Multiplex Takes Center Stage
May 05, 2021 04:53 ET | Research and Markets
Dublin, May 05, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease 2021-2025: Market Analysis by Syndrome, Plex, Place, and Country with COVID-19 Impact & Forecast,...
22157.jpg
Molecular Diagnostics for Infectious Disease Markets, 2025 - C19Dx Demand Sweeps Over the Globe
January 29, 2021 04:13 ET | Research and Markets
Dublin, Jan. 29, 2021 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive...
22157.jpg
The Global Market for Molecular Diagnostics Infectious Disease 2021-2025
November 24, 2020 17:23 ET | Research and Markets
Dublin, Nov. 24, 2020 (GLOBE NEWSWIRE) -- The "Molecular Diagnostics for Infectious Disease By Syndrome, Plex, Place and by Country. With COVID-19 Impact & Forecasting/Analysis, and Executive...
ContraFect_LOGO_Web.jpg
ContraFect Announces Plan for a Single Phase 3 Superiority Design Study of Exebacase Following Successful End-of-Phase 2 Meeting with FDA
October 02, 2019 07:00 ET | ContraFect Corporation
Primary Endpoint of Clinical Response at Day 14 in Patients with Methicillin-Resistant Staph aureus (MRSA) Bacteremia, including Right-Sided Endocarditis Study Initiation Planned by Year-End 2019 ...
ContraFect_LOGO_Web.jpg
ContraFect Awarded $7.2 Million USAMRDC Grant to Support the Advancement of Lysin Candidate CF-296
June 06, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., June 06, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect Announces Presentation at the International Society of Cardiovascular Infectious Diseases Symposium
June 03, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., June 03, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect Announces Publication of Paper on Recent Exebacase Data in Antimicrobial Agents and Chemotherapy Journal
May 31, 2019 07:00 ET | ContraFect Corporation
YONKERS, N.Y., May 31, 2019 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of biologic therapies for...
ContraFect_LOGO_Web.jpg
ContraFect to Present at Cantor Antibiotics Summit
January 11, 2018 07:00 ET | ContraFect Corporation
YONKERS, N.Y., Jan. 11, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (NASDAQ:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody...